MedTrace Logo

The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)

NCT02393183 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2023-09-28

No results posted yet for this study

Summary

This randomized clinical trial is designed to evaluate the effect of selected antioxidant vitamins and minerals supplement named as ASTED:

1. β- Carotene (30 mg)
2. Vit C (100 mg)
3. Vit E (Alpha-Tocopherol Acetate): 60-200 IU
4. Calcium phosphate dihydrate (40 mg)
5. Zinc oxide (4 mg, elemental)
6. Copper gluconate (3.5 mg)
7. Sodium selenite 23 mg= Selenium 100 µg
8. Nicotinamide (a form of vit.B3) (10 mg)

in patients with mild Thyroid eye disease according to EUGOGO classification. To be given twice a day.

Conditions

  • Thyroid Eye Disease

Interventions

DRUG

ASTED

A tablet of ASTED will be taken twice a day

DIETARY_SUPPLEMENT

Selenium

A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day

OTHER

Placebo

A tablet of Placebo (same shape and color) will be taken twice a day

Sponsors & Collaborators

  • Iran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohsen B Kashkouli, MD · Iran University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-15
Primary Completion
2022-06-15
Completion
2022-12-15

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393183 on ClinicalTrials.gov